In mid-November, the European Commission tabled the long-awaited review of its Bioeconomy Strategy and Action Plan. European Biotechnology spoke with Waldemar Kütt, Head of Unit Bioeconomy Strategy, about the development the bioeconomy has made since its launch in 2012 by the European Commission and the instruments needed to attract investments, make it circular, and create a stable policy environment for companies and investors.
Merging industries
OpinionIn mid-November, the European Commission tabled the long-awaited review of its Bioeconomy Strategy and Action Plan. European Biotechnology spoke with Waldemar Kütt, Head of Unit Bioeconomy Strategy, about the development the bioeconomy has made since its launch in 2012 by the European Commission and the instruments needed to attract investments, make it circular, and create a stable policy environment for companies and investors.
Cancer is a gate-opener to data sharing
Latest NewsA brand-new survey conducted by auditing and consulting firm PwC and Strategy& has found out that 80% of data protection-prone Germans would share their data in case of being diagnosed with cancer. The results show that cancer could act as a gate-opener to approaches in personalised medicine that depend on the accessiblity of patient data.
Bacterial duo triggers colorectal cancer
Latest NewsUS and Dutch researchers have found that carcinogenic E. coli and B. fragilis versions in the gut of patients who developed precancerous polyps early in life trigger development of colon cancer by secreting proinflammatoy signals, depleting mucus and inducing DNA damage.
CRISPR corrects clustered DMD mutations
Latest NewsUsing CRISPR-Cas 9 genome editing, US and German stem cell researchers have corrected clustered mutations in the dystrophin gene in heart mucle cells obtained from induced pluripotent stem cells of patients with Duchenne muscular dystrophy (DMD).
Rentschler Biopharma SE appoints Dr. Ralf Otto as COO
AppointmentsRentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, today appointed Dr. Ralf Otto as Chief Operating Officer (COO), effective February 1, 2018.
EPO bows to pressure from industry
Latest NewsFollowing critisism from the industry, the European Patent Office has drafted a proposal to allow exemptions to its Early Certainty Initiative. Industry associations had pressed the EPO not to limit the time to grant a patent to 12 months arguing it would have detrimental effects on the life sciences sector.
EU ombudsman soft-sells safety concerns on HPV jabs
BackgroundA complaint against the EMAs handling of a referral procedure related to potential side effects of Sanofi/MSDs HPV vaccine Gardasil and GSKs HPV jab Cervarix, filed by the Nordic Cochrane Centre and physicians, has been rejected by the European Ombudsman.
Storm Therapeutics Appoints Nobel Prize Winner Thomas Cech as Scientific Advisor
AppointmentsStorm Therapeutics today announced the appointment of Nobel Prize Winner Professor Thomas Cech as a Scientific Advisor. This appointment follows STORM Therapeutics successful Series A Financing Extension announced in January 2018.
Sanofi acquiring Ablynx
Latest NewsBriefly after Belgian nanobody maker Ablynx rejected a €2.3bn take-over bid of Novo, its board accepted a €3.9bn tender of its R&D partner Sanofi. It’s the second large take-over of Sanofi this month.
EMA recommends seven new drugs for market
Latest NewsThe European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) greenlighted seven medicines for approval at its January 2018 meeting, including one orphan medicine, and one biosimilar.